Brain dopamine receptors: A primer on their current status, basic and clinical

Harvard Review of Psychiatry

Volumn 3, Issue 6, 1996, Pages 301-325

  Baldessarini, Ross J ^a   Tarazi, Frank I ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; AMINOTETRALIN DERIVATIVE; APOMORPHINE; APORPHINE DERIVATIVE; ARACHIDONIC ACID; BENZAMIDE DERIVATIVE; BRAIN RECEPTOR; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; EMONAPRIDE; ERGOLINE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; OXIDOPAMINE; PETHIDINE; PHENOTHIAZINE DERIVATIVE; PRAMIPEXOLE; RECEPTOR SUBTYPE; RESERPINE; SPIPERONE; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; DOPAMINERGIC SYSTEM; HUMAN; MOLECULAR CLONING; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR GENE; REVIEW;

EID: 0029879485     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229609017200     Document Type: Review

References (280)

1. Creese I, Burt D, Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
2. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261: 717-9.
3. Baldessarini R. Schizophrenia. N Engl J Med 1977;297:988-95.
4. Baldessarini R. Drugs and the treatment of psychiatric disorders. In: Harden W, Rudin W, Molinoff PB, Rall T, eds. Goodman and Gilman's The pharmacologic basis of therapeutics. New York: McGraw-Hill, 1996:399-459.
5. Baldessarini R. Chemotherapy in psychiatry: principles and practice. 3rd ed. Cambridge, Massachusetts: Harvard University Press [In press].
6. Meltzer H, Stahl S. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976;2:19-76.
7. Wyatt R, Kirsch D, DeLisi L. Schizophrenia: biochemical, endocrine and immunological studies. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1989:717-32.
8. Davis K, Kahn R, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
9. Fibiger H. The dopamine hypotheses of schizophrenia and mood disorders: contradictions and speculations. In: Willner P, Scheel-Krüger J, eds. The mesolimbic dopamine system: from motivation to action. New York: Wiley, 1991:615-35.
10. Seeman P. Dopamine receptors: clinical correlates. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:295-302.
11. Baldessarini R. Dopamine receptors in clinical medicine. In: Neve K, Neve R, eds. The dopamine receptors. Totowa, New Jersey: Humana [In press].
12. Kuhar M, Ritz M, Boja J. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14: 299-302.
13. Bannon M, Granneman J, Kapatos G. The dopamine transporter: potential involvement in neuro-psychiatric disorders. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:79-88.
14. Iversen S. Brain dopamine system and behavior. In: Iversen L, Iversen S, Snyder S, eds. Handbook of psychopharmacology, vol 8. New York: Plenum, 1977:333-78.
15. Benninger R. The role of dopamine in locomotor activity and learning. Brain Res Rev 1983;6:173-96.
16. Doane B, Livingston K, eds. The limbic system: functional organization and clinical disorders. New York: Raven, 1986.
17. Willner P, Scheel-Krüger J, eds. The mesolimbic dopamine system: from motivation to action. New York: Wiley, 1991.
18. Goldman-Rakic P. Cellular basis of working memory. Neuron 1995;14:477-85.
19. Benson D, Blumer D, eds. Psychiatric aspects of neurologic disease. New York: Grune & Stratton, 1975.
20. Marsden D. Basal ganglia disease. Lancet 1982;2:21-7.
21. Tarsy D, Baldessarini R. Movement disorders induced by psychotherapeutic drugs. In: Shah N, Donzid A, eds. Movement disorders. New York: Plenum, 1986:365-89.
22. Cohen D, Bruun R, Leckman J, eds. Tourette's syndrome and tic disorders: clinical understanding and treatment. New York: Wiley, 1988.
23. Carlsson A. Thirty years of dopamine research. Adv Neurol 1993;60:1-17.
24. Baldessarini RJ. Fifty years of biomedical psychiatry and Psychopharmacology. In: Menninger R, Nemiah J, eds. Fifty years of American psychiatry. Washington, DC: American Psychiatric Press [In press].
25. Cooper J, Bloom F, Roth R, eds. Dopamine. In: The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press, 1991:285-337.
26. Moore K, Lookingland K. Dopaminergic neuronal systems in the hypothalamus. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:245-56.
27. Graybiel A. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-54.
28. Alexander G, Crutcher M. Functional architecture of basal ganglia circuits: neuronal substrates of parallel processing. Trends Neurosci 1990;13:266-71.
29. Gerfen C. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-9.
30. Chiodo L, Freeman A, Bunney B. Dopamine autoreceptor signal transduction and regulation. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:221-6.
31. Roth R, Elsworth J. Biochemical pharmacology of midbrain dopamine neurons. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:227-44.
32. 2 autoreceptor activation. Eur J Pharmacol 1990;185:217-21.
33. Booth R, Wyrick S, Baldessarini R, Kula N, Myers A, Mailman R. A new sigma-like receptor recognized by novel phenylaminotetralins. Mol Pharmacol 1993;44:1232-9.
34. Kebabian J, Calne D. Multiple receptors for dopamine. Nature 1979;277:93-6.
35. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 32:229-313.
36. 3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors. Brain Res 1981;213:227-89.
37. Marangos P, Campbell I, Cohen R, eds. Brain receptor methodologies. New York: Academic, 1984.
38. 3H]SCH-23390. Eur J Pharmacol 1985;108: 323-5.
39. Yamamura H, ed. Neurotransmitter receptor binding. New York: Raven, 1985.
40. 2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. J Neurosci 1987;7:1352-60.
41. 14C-compounds. Brain Res 1988;459:105-19.
42. 2 receptor. J Endocrinol 1992;134:227-33.
43. 2 dopamine receptor distribution in the rodent CNS using anti-peptide antisera. Brain Res 1993;609:71-80.
44. 3 dopamine receptor: pharmacologic properties and development of antibodies. J Pharmacol Exp Ther 1993;264:1002-11.
45. 3 subtypes. Brain Res 1994;849:95-100.
46. Civelli O, Bunzow J, Grandy D, Zhou Q, Van Tol H. Molecular biology of the dopamine receptors. Eur J Pharmacol 1991; 207:277-86.
47. Schwartz J, Giros B, Martres M, Sokoloff P. The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 1992;4:99-108.
48. Strange P. Interesting times for dopamine receptors. Trends Neurosci 1991;14:43-5.
49. Sibley D, Monsma F. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992;13:61-9.
50. Civelli O, Bunzow J, Grandy D. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993;32: 281-307.
51. Jarvie K, Caron M. Heterogeneity of dopamine receptors. Adv Neurol 1993;60:325-33.
52. O'Dowd B. Structures of dopamine receptors. J Neurochem 1993;60:804-16.
53. Sibley D, Monsma F, Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 1993;35:391-415.
54. Sokoloff P, Schwartz J. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995;16:270-5.
55. Civelli O. Molecular biology of the dopamine receptor subtypes. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:55-62.
56. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995;346:743-9.
57. Seeman P. Dopamine receptors and psychosis. Sci Am 1995; 2(5):28-37.
58. Neve K, Neve R, eds. The dopamine receptors. Totowa, New Jersey: Humana [In press].
59. Duman R, Nestler E. Signal transduction pathways for catecholamine receptors. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:303-20.
60. 2 receptor cDNA. Nature 1988;336:783-7.
61. 2 dopamine receptor. Proc Natl Acad Sci U S A 1989;86:9762-6.
62. 2 dopamine receptor subtype. Proc Natl Acad Sci U S A 1989;86:10134-8.
63. 2 receptors expressed in different cell types. J Biol Chem 1990;265: 10320-6.
64. 2 receptor are functionally distinct. Mol Endocrinol 1992;6:920-6.
65. +) channel in dopaminergic neurons of the rat substantia nigra. Neurosci Lett 1992;141:213-7.
66. 2 receptor genes. Neurochem Int 1992;21:91-8.
67. 2 receptor: two molecular forms generated by alternative splicing. EMBO J 1989;8:4025-34.
68. 2 dopamine receptor isoforms. Nature 1989;342:923-6.
69. 2 dopamine receptors produced by alternative RNA splicing. Nature 1989;342:926-9.
70. 2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Mol Pharmacol 1994;45:878-89.
71. 3 receptors. Mol Pharmacol 1993;43:749-54.
72. 2A receptor gene: identification of alternative transcripts and a variant donor splice site. Biochemistry 1990;29:1367-71.
73. 3) as a target for neurolepties. Nature 1990;347: 146-51.
74. 3 receptor and chromosome identification. C R Acad Sci III 1990;311:501-8.
75. 2 receptor mRNA. Brain Res 1991;564:203-19.
76. 3 dopamine receptor produced through various patterns of alternative splicing. Biochem Biophys Res Commun 1991;176:1584-92.
77. 3 dopamine receptor. Arzneimittelforschung 1992;42:224-30.
78. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 1992; 89:8155-9.
79. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A 1995;92:1719-23.
80. 3 receptor in the rat brain. Neuroscience 1995;65:731-45.
81. 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. Eur J Pharmacol 1978;49:201-2.
82. 3H-spiperone binding sites in various areas of the rat limbic system. Mol Pharmacol 1979;15:506-14.
83. 3 receptors in vivo. Eur J Pharmacol 1992;218: 373-5.
84. 3 receptors in rat brain. Eur J Pharmacol 1992;211: 189-94.
85. 3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. J Pharmacol Exp Ther 1993;264:991-1001.
86. 2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guasine nucleotide. J Neurochem 1985;44:1925-35.
87. 3 dopamine receptor ligand. J Med Chem 1993;36:1499-1500.
88. 3 receptors in rat olfactory tubercle. J Pharmacol Exp Ther 1994;268:935-42.
89. 3 dopamine receptors. Eur J Pharmacol 1993;239:269-70.
90. 3 dopamine receptors. Neuropsychopharmacology 1995;12:335-45.
91. 3 receptors. Eur J Pharmacol 1995;272:R1-3.
92. 3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 1994;260:177-81.
93. 3-selective aminotetralin on dopamine metabolism in rat brain regions in vitro and in vivo. Brain Res 1994;662:283-8.
94. 2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Neuropsychopharmacology 1995; 12:139-45.
95. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-4.
96. 4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system. New Biol 1992;4: 137-46.
97. Meador-Woodruff J, Grandy D, Van Tol H, Damask S, Little K, Civelli O, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994;10:239-48.
98. 4 receptors elevated in schizophrenia. Nature 1993;365:441-5.
99. 4 receptor. In: Niznik H, ed. Dopamine receptors and transporters. New York: Dekker, 1994:189-204.
100. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995;15:2186-91.
101. 4 receptors increased in schizophrenia? J Neurochem 1994;63:1576-7.
102. 4 receptor variants in the human population. Nature 1992;358:149-52.
103. 4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269:11813-9.
104. Baldessarini R, Frankenburg F. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
105. 4. Neuropsychopharmacology 1992;7:261-84.
106. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995;120:365-8.
107. Baldessarini R, Gardner D, Garver D. Conversions from clozapine to other antipsychotics. Arch Gen Psychiatry 1995; 52:1071-82.
108. Baldessarini R, Arana G, Kula N, Campbell A, Harding M. Preclinical studies of the pharmacology of aporphines. In: Corsini G, Gessa G, eds. Apomorphine and other dopaminomimetics, vol 1: Basic pharmacology. New York: Raven, 1981: 219-28.
109. Campbell A, Baldessarini R, Teicher M, Neumeyer J. S(+)-Aporphines: selective inhibition of excitatory effects of dopamine injected into rat limbic system. Neuropharmacology 1985;24:391-9.
110. Campbell A, Baldessarini R, Teicher M, Neumeyer J. Behavioral effects of apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-n-propylnorapomorphine in rat. Psychopharmacology 1986;88:158-64.
111. Campbell A, Yeghiayan S, Baldessarini R, Neumeyer J. Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology 1991;103:323-9.
112. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993;236: 483-6.
113. 4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Eur J Pharmacol 1993;233:173-4.
114. Baldessarini R, Kula N, Zong R, Neumeyer J. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur J Pharmacol 1994;254:199-203.
115. Booth R, Baldessarini R, Kula N, Gao Y, Zong R, Neumeyer J. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines. Mol Pharmacol 1990;38:92-101.
116. Campbell A, Baldessarini R, Neumeyer J. Altered spontaneous behavior and responses to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 1993;111:351-8.
117. Baldessarini R, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer J. Effects of aporphine isomers on rat prolactin. Neurosci Lett 1994;176:269-71.
118. 1 dopamine receptor. Nature 1990;347:72-6.
119. 1 dopamine receptors. Nature 1990;347:76-80.
120. 1 receptor encoded by an intronless gene on chromosome 5. Nature 1990;347: 80-3.
121. 1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A 1990;87:6723-7.
122. 2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology 1991;5:231-42.
123. 1 autoreceptor function: possible expression in developing rat prefrontal cerebral cortex and striatum. Dev Brain Res 1991;63:229-35.
124. 1 dopamine receptor. Nature 1990;47:72-6.
125. 2+ mobilization in Xenopus oöcytes. Proc Natl Acad Sci U S A 1990;87:2196-200.
126. Hemmings H, Greengard P. DARPP-32, a dopamine and 3′,5′-monophosphate-regulated phosphoprotein: regional, tissue and phylogenetic distribution. J Neurosci 1986;6:1469-81.
127. Hemmings H, Walaas S, Ouiment C, Greengard P. Dopaminergic regulation of protein phosphorylation in the striatum: DARPP-32. Trends Neurosci 1987;10:377-83.
128. 1 and DARPP-32 gene expression in the rat striatum: an in situ hybridization study. Mol Brain Res 1992;12:131-9.
129. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-32.
130. LeMoine C, Normand E, Guitteny A, Fouque B, Teoule R, Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc Natl Acad Sci U S A 1990;87: 230-4.
131. Surmeier J, Reiner A, Levine M, Ariano M. Are neostriatal dopamine receptors co-localized? Trends Neurosci 1993;16: 299-305.
132. 1. Nature 1991;350:614-9.
133. 5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci U S A 1991;88:9175-9.
134. 5 pseudogene. Biochem Biophys Res Commun 1991;181:16-21.
135. 1b) and its pseudogene. J Biol Chem 1991;266:22427-35.
136. 5 receptor. J Receptor Res 1993;13:73-90.
137. 1 dopamine receptor. Synapse 1987;1:347-88.
138. 2 dopamine receptor interactions: neuroscience and psychopharmacology. New York: Academic, 1993.
139. 1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? Trends Pharmacol Sci 1990;11:406-10.
140. 1-DA receptor antagonist SCH-39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 1995; 121:317-22.
141. 1-dopamine receptor antagonist SCH-39166 in acutely ill schizophrenic patients. Psychopharmacology 1995;121:309-16.
142. Schloss P, Mayser W, Betz H. Neurotransmitter transporters. FEBS Lett 1992;307:76-80.
143. Lesch K, Bengel D. Neurotransmitter reuptake mechanisms: targets for drugs to study and treat psychiatric, neurological and neurodegenerative disorders. CNS Drugs 1995;4:302-22.
144. 3H]dopamine. Neuropharmacology 1990;29:475-86.
145. Carroll F, Lewin A, Boja J, Kuhar M. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 1992;35:969-81.
146. Kitayama S, Shimada S, Xu H, Markham L, Donovan D, Uhl G. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A 1992;89:7782-5.
147. Weiner H, Hashim A, Lajtha A, Sershen H. Chronic deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 1989;163:191-4.
148. Kula N, Baldessarini R. Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacology 1991;30:89-92.
149. Rostène W, Boja J, Scherman D, Carroll I, Kuhar M. Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum. Eur J Pharmacol 1992;218:175-7.
150. Floor E, Leventhal P, Wang Y, Meng L, Chen W. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem 1995;64:689-99.
151. Langston J, Ballard P, Tetrud I, Irwin I. Chronic parkinsonism in humans due to a product of pyridine-analog synthesis. Science 1983;219:79-80.
152. Kula N, Baldessarini R, Campbell A, Finklestein S, Ram V, Neumeyer J. Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. Life Sci 1984;34:2567-75.
153. +) within catecholaminergic neurons. Neurotoxicology 1991;12:285-302.
154. 3H]tyramine in dopaminergic and nondopaminergic brain regions. J Neurochem 1993; 60:758-60.
155. 2 receptor. Proc Natl Acad Sci U S A 1991;88: 8111-5.
156. Hibert M, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991;40:8-15.
157. Tamminga C, Dahl S. Molecular model: G protein-coupled receptor. Am J Psychiatry 1994;151:499.
158. 1 dopamine receptor. Biochem Pharmacol 1992;44:325-34.
159. 2 receptors: role of disulfide and sulfhydryl groups. Neurochem Res 1992;17:749-59.
160. Gilman A. G-proteins: transducers of receptor generated signals. Ann Rev Biochem 1987;56:615-49.
161. Kleuss C, Raw A, Lee E, Sprang S, Gilman A. Mechanism of GTP hydrolysis by G-protein α-subunits. Proc Natl Acad Sci U S A 1994;91:9828-31.
162. Krupinski J, Coussen F, Bakalyan H, Tang WJ, Feinstein P, Orth K, et al. Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure. Science 1989;244: 1558-64.
163. 2+/calmodulin-insensitive adenylyl cyclase from rat brain. Proc Natl Acad Sci U S A 1991;88:10173-7.
164. Gao B, Gilman A. Cloning and expression of a widely distributed (type IV) adenylyl cyclase. Proc Natl Acad Sci U S A 1991;88:10178-82.
165. Harris J, Baldessarini R, Morgenroth V, Roth R. Activation by cyclic 3′,5′-adenosine monophosphate of tyrosine hydroxylase in the rat brain. Proc Natl Acad Sci U S A 1975;72:789-93.
166. Zigmond R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Ann Rev Neurosci 1989;12:415-61.
167. 2 synthesis-modulating receptors are present in the striatum of the guinea pig. Nouropharmacology 1992;31: 95-101.
168. Goldstein M. Long- and short-term regulation of tyrosine hydroxylase. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:189-95.
169. Baldessarini R. Release of catecholamines. In: Iversen L, Iversen S, Snyder S, eds. Handbook of psychopharmacology, vol 3. New York, Plenum, 1975:37-137.
170. Langer S. Presynaptic regulation of release of catecholamines. Pharmacol Rev 1981;32:337-62.
171. Chesselet M. Presynaptic regulation of neurotransmitter release in brain. Neuroscience 1984;12:347-75.
172. 3H]dopamine and analogous monoamines from rat striatal tissue. Cell Mol Neurobiol 1988;8:205-16.
173. Kemel M, Desban M, Glowinski J, Gauchy C. Distinct presynaptic control of dopamine release in striosomal and matrix areas of the cat caudate nucleus. Proc Natl Acad Sci U S A 1989;86:9006-10.
174. 2 receptor. Trends Pharmacol Sci 1989;10: 74-7.
175. 2 receptor synergism. Nature 1991;353:164-7.
176. 2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 1991;39:364-9.
177. Undie A, Friedman E. Selective dopaminergic mechanism of dopamine and SKF-38393 stimulation of inositol phosphate formation in rat brain. Eur J Mol Pharmacol 1992;226:297-302.
178. 2 receptor mRNA in rat striatum. Dev Brain Res 1991;63:95-104.
179. 1-dopamine receptors and dopamine content in the rat striatum. Dev Brain Res 1987;35:283-90.
180. 2 receptor sites in rat striatum. Dev Brain Res 1989;49:123-36.
181. Broaddus W, Bennett J. Postnatal development of striatal dopamine function. Dev Brain Res 1990;52:73-7.
182. 2 receptor gene expression in the rat striatum during ontogeny: an in situ hybridization study. Dev Brain Res 1991;60:79-87.
183. 1 receptors in the medial prefrontal cortex, striatum and nucleus accumbens of normal and neonatal 6-hydroxydopamine treated rats: a quantitative autoradiographic analysis. Dev Brain Res 1991;62:109-14.
184. 2 receptor messenger RNAs during development. Dev Brain Res 1991;59:249-51.
185. De Vries T, Mulder A, Schoffelmeer A. Differential ontogeny of functional dopamine and muscarinic receptors mediating presynaptic inhibition of neurotransmitter release and regulation of adenylate cyclase activity in rat striatum. Dev Brain Res 1992;66:91-6.
186. 3H]YM-09151-2 binding sites in human fetal forebrain. Biol Psychiatry 1994; 35:562-9.
187. 1 selective agents. Neuropharmacology 1989;28:99-101.
188. 1 receptors attenuate excitatory and inhibitory limbic inputs to the shell region of the rat nucleus accumbens studied in vitro. J Neurophysiology 1992;67:1325-34.
189. Creese I, Burt D, Snyder S. Dopamine receptor binding accompanies lesion-induced behavioral supersensitivity. Science 1977;197:596-8.
190. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Mol Brain Res 1991;11:161-6.
191. 2 receptor mRNA levels caused by lesion of the nigrostriatal pathway. Eur J Neurosci 1992;4:663-72.
192. 2 dopamine receptor mRNA during ontogenesis and chronic antagonist treatment. Life Sci 1991;50:383-96.
193. 1 agonists SKF-38393 and A-68930 in neonatal 6-OH-DA-lesioned rats. J Pharmacol Exp Ther 1992;262:855-65.
194. 2 receptors. Synapse 1992;11:35-46.
195. 1 and forskolin binding sites in rat striatum. Posters Neurosci 1991;1:9-11.
196. Frohna P, Neal-Beliveau B, Joyce J. Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs. Neuroscience 1995;68:505-18.
197. O'Boyle K, Gavin K, Harrison N. Chronic antagonist treatment does not alter the mode of interaction of dopamine with rat striatal dopamine receptors. J Recept Res 1993;13:329-39.
198. Baldessarini R, Tarsy D. Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Ann Rev Neurosci 1980;3:23-41.
199. s-protein coupling. Eur J Pharrnacol 1991;207: 271-4.
200. Mileson B, Lewis M, Mailman R. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res 1991;561:1-10.
201. 2 synergism are unrelated to changes in striatal receptor density. Synapse 1992;12:14-26.
202. 2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine - induced denervation. Biochem Pharmacol 1992;44:73-82.
203. 1 dopamine receptor associated adenylyl cyclase activity in rat striatum. Biochem Pharmacol 1992;44:83-91.
204. Fibiger H, Lloyd K. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984;7: 462-5.
205. Jeste D, Doongaji D, Linnoila M. Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia. Br J Psychiatry 1984; 144:177-80.
206. Goldstein M, Lew J, Nakamura S, Battista A, Lieberman A, Fuxe K. Dopaminephilic properties of ergot alkaloids. Fed Proc 1978;37:2202-6.
207. 3H]dihydroxy - 1,2,3,4 - tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics. J Neurosci 1982;2:895-906.
208. 1 agonist. In: Dahlström A, Belmaker R, Sandler M, eds. Progress in catecholamine research - central aspects. New York: Liss, 1988:59-64.
209. 1 dopamine receptor. Neuropharmacology 1989;28:401-5.
210. 1 full agonist. J Med Chem 1990;33:1756-64.
211. 1 receptor. Eur J Pharmacol 1991;199:209-19.
212. 1 dopamine receptor: synthesis and characterization of R(+) and S(-) enantiomers of 3-allyl-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J Med Chem 1992;35:1466-71.
213. 2 agonist in primates. Clin Neuropharmacol 1992;15:307-9.
214. Markstein R, Seiler M, Jaton A, Briner U. Structure-activity relationship and therapeutic uses of dopaminergic ergots. Neurochem Int 1992;20(suppl):211-4.
215. 2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 1992;42:432-8.
216. 1 dopamine receptor sites, in rat brain tissue. Biochem Pharmacol 1989;38:473-80.
217. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991;17:289-309.
218. Meltzer H, ed. Novel antipsychotic drugs. New York: Raven, 1992.
219. Lewander T. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Acta Psychiatr Scand 1994;89:64-7.
220. Sedvall G. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 1992;7:41-54.
221. 2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. Mol Pharmacol 1992;42:856-63.
222. Cohen B, Tsuneizumi T, Baldessarini R, Campbell A, Babb S. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 1992;108:338-44.
223. Meltzer H, Nash J. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604.
224. Leysen J, Janssen P, Gommeren W, Wynants J, Pauwels P, Janssen P, et al. In vitro and in vivo receptor bindings and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41:494-508.
225. 2 receptors. Psychopharmacology 1993;112(suppl):S40-54.
226. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G, et al. Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
227. Kane J, ed. Risperidone: new horizons for the schizophrenic patient. J Clin Psychiatry 1994;55(5 suppl):1-35.
228. Marder S, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
229. Lieberman J. Understanding the mechanism of action of atypical antipsychotic drugs: review of compounds in use and development. Br J Psychiatry 1993;163(suppl 22):7-18.
230. Moore N, Calligaro D, Wong D, Bymaster F, Tye N. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2:281-93.
231. Fleischhacker W. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 1995;91(suppl 388): 24-30.
232. Campbell A, Baldessarini R, Cremens C, Teicher M, Marsh E. Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 1989;2:209-24.
233. Coward D, Dixon A, Urwyler S, White T, Enz A, Karobath M, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther 1990;252:279-85.
234. 2 dopamine autoreceptor selective drugs. Life Sci 1990;47:361-76.
235. Svensson K, Ekman A, Piercey M, Hoffmann W, Lum J, Carlsson A. Effects of the partial dopamine receptor agonists SDZ-208-911, SDZ-208-912 and terguride on central monoamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1991;344:263-74.
236. Campbell A, Baldessarini R, Yeghiayan S. Antidopaminergic actions of dopaminergic ergolines in limbic and extrapyramidal regions of rat forebrain. Brain Res 1992;592:348-52.
237. Schilling J, Adamus W, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992;51:541-8.
238. Meller E, Bohmaker K, Namba Y, Friedhoff A, Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 1987;296:5-14.
239. Cox R, Neumeyer J, Waszczak B. Effects of N-propylnorapomorphine enantiomers on single unit activity of midbrain dopamine neurons. J Pharmacol Exp Ther 1988;247:355-62.
240. Meller E, Enz A, Goldstein M. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol 1988;155:151-4.
241. Cox R, Waszczak B. Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording after partial inactivation of receptors by EEDQ. Mol Pharmacol 1989;34:125-31.
242. Martin L, Cox R, Waszczak B. Efficacy and potency comparisons among aporphine enantiomers: effects on dopamine neurons in substantia nigra of rat. Neuropharmacology 1990; 29:135-44.
243. Baldessarini R, Marsh E, Kula N, Zong R, Gao Y, Neumeyer J. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions. Biochem Pharmacol 1990; 40:417-23.
244. Hedberg A, Gerber J, Nies A, Wolfe B, Molinoff P. Effects of pindolol and propranolol on beta adrenergic receptors on human lymphocytes. J Pharmacol Exp Ther 1986;239:117-23.
245. 1 receptor sequence is normal, but has DNA polymorphisms. Neuropsychopharmacology 1993;8:131-5.
246. 2. Neuropsychopharmacology 1993;8:137-42.
247. 3H-apomorphine in schizophrenic brains. Nature 1978;274:897-900.
248. Mackay A, Iversen L, Rossor M, Spokes E, Bird E, Arregui A, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982;39:991-7.
249. 3H-Spiperone binding sites in postmortem brains from schizophrenic patients: relationship to drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989;75:1-10.
250. 3 receptors are elevated in schizophrenic brain and decreased by neuroleptic treatment [Abstract]. Schizophr Res 1995;15:61.
251. 3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A 1993;90:8942-6.
252. 76Br-spiperone in the striata of schizophrenic patients and controls. Nucl Med Commun 1986;7: 599-607.
253. 2 dopamine receptors in drug-naïve schizophrenics. Science 1986;234:558-63.
254. Baron J, Martinot J, Cambon H, Boulenger J, Poirier M, Caillard V, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 1989;98:463-72.
255. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990;147:44-50.
256. 2 receptors. Chem Pharm Bull (Tokyo) 1992;40:1793-8.
257. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Hum Psychopharmacol 1992;7:157-65.
258. 1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992;106:14-8.
259. Melison R, Larulle M, Innis R. positron and single photon emission tomography. In: Bloom F, Kupfer D, eds. Psychopharmacology: fourth generation of progress. New York: Raven, 1995:865-79.
260. 2 receptors. Am J Psychiatry 1991;148:1607-8.
261. 2 receptor with iodine-iodosuride: results in supranuclear palsy. J Nucl Med 1992;33:1481-5.
262. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202.
263. 123I-IBZM SPECT in neuroleptic-free schizophrenic patients [Abstract]. Schizophr Res 1995;15:88.
264. 2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 1994; 164:27-34.
265. 2 dopamine receptors in Tourette's syndrome and manic-depressive illness. J Nucl Med 1988;29:820-1.
266. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994;35:128-32.
267. 2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 1994;35:880-5.
268. Baldessarini R, Cohen B, Teicher M. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
269. Cambon H, Baron J, Boulenger J, Loc'h C, Zarifian E, Mazière B. In vivo assay for neuroleptic receptor binding in the striatum. Br J Psychiatry 1987;151:824-30.
270. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45: 71-6.
271. Wolkin A, Brodie J, Barouche F, Rotrosen J, Wolf A, Smith M, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989;46:482-4.
272. 2-receptor blockade by typical and atypical neuroleptics [Letter]. Lancet 1992;339:497.
273. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenia patients. Biol Psychiatry 1993;33:227-35.
274. Persico A, Wang Z, Black D, Andreasen N, Uhl G, Crowe R. The dopamine transporter gene and schizophrenia spectrum disorders: exclusion of close linkage. Am J Psychiatry 1995; 152:134-6.
275. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 1987;49:617-21.
276. Seeman P, Niznik H. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4: 2737-44.
277. 3H]GBR-12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biol Psychiatry 1995;37:175-82.
278. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-61.
279. 11C]WIN-35428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-31.
280. Innis R, Seibyl J, Scanley B, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965-9.